MX2023005501A - Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer. - Google Patents
Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.Info
- Publication number
- MX2023005501A MX2023005501A MX2023005501A MX2023005501A MX2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- cdk4
- cancer
- combinations
- treatment
- Prior art date
Links
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112217P | 2020-11-11 | 2020-11-11 | |
| US202163166060P | 2021-03-25 | 2021-03-25 | |
| PCT/US2021/058775 WO2022103834A1 (en) | 2020-11-11 | 2021-11-10 | Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005501A true MX2023005501A (es) | 2023-07-27 |
Family
ID=78821168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005501A MX2023005501A (es) | 2020-11-11 | 2021-11-10 | Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230404963A1 (https=) |
| EP (1) | EP4243807A1 (https=) |
| JP (1) | JP2023550035A (https=) |
| KR (1) | KR20230117574A (https=) |
| AU (1) | AU2021378944A1 (https=) |
| CA (1) | CA3198173A1 (https=) |
| MX (1) | MX2023005501A (https=) |
| WO (1) | WO2022103834A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250127759A1 (en) * | 2021-12-02 | 2025-04-24 | Pfizer Inc. | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer |
| CA3264343A1 (en) * | 2022-08-10 | 2024-02-15 | Syndevrx, Inc. | METAP2 INHIBITORS FOR THE TREATMENT OF PULMONARY FIBROSIS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US20130137831A1 (en) * | 2010-05-25 | 2013-05-30 | John S. Petersen | Optimized drug conjugates |
| CA3239447A1 (en) * | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| WO2019070755A1 (en) * | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| JP2022512826A (ja) * | 2018-10-26 | 2022-02-07 | シンデブルックス，インコーポレイティド | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 |
-
2021
- 2021-11-10 WO PCT/US2021/058775 patent/WO2022103834A1/en not_active Ceased
- 2021-11-10 AU AU2021378944A patent/AU2021378944A1/en active Pending
- 2021-11-10 US US18/036,565 patent/US20230404963A1/en active Pending
- 2021-11-10 JP JP2023528148A patent/JP2023550035A/ja active Pending
- 2021-11-10 KR KR1020237018920A patent/KR20230117574A/ko active Pending
- 2021-11-10 EP EP21819673.1A patent/EP4243807A1/en active Pending
- 2021-11-10 MX MX2023005501A patent/MX2023005501A/es unknown
- 2021-11-10 CA CA3198173A patent/CA3198173A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021378944A1 (en) | 2023-06-15 |
| US20230404963A1 (en) | 2023-12-21 |
| EP4243807A1 (en) | 2023-09-20 |
| JP2023550035A (ja) | 2023-11-30 |
| WO2022103834A1 (en) | 2022-05-19 |
| KR20230117574A (ko) | 2023-08-08 |
| CA3198173A1 (en) | 2022-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009563A (es) | Combinacion farmaceutica que comprende tno155 y ribociclib. | |
| MX2022004513A (es) | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). | |
| MX2025003444A (es) | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38) | |
| EP4249000A3 (en) | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| MX2021009562A (es) | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. | |
| MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
| PH12020551760A1 (en) | Pyridazinones as parp7 inhibitors | |
| PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| JOP20220167A1 (ar) | مثبطات sarm1 | |
| MX2022012471A (es) | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. | |
| MX2024008115A (es) | Tratamiento conjunto para tratamiento contra el cancer. | |
| AU2018238202A8 (en) | Combination therapy for the treatment or prevention of tumours | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| EP4674415A3 (en) | Azaquinolines as inhibitors of cd38 | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| MX2025008920A (es) | Inhibidores de parp1 triciclicos y usos de estos | |
| MX395085B (es) | Tratamiento conjunto contra tipos de cancer hematologico. | |
| PH12021552147A1 (en) | Rad51 inhibitors | |
| WO2024006292A3 (en) | Methods of treating cancer | |
| MX2024001243A (es) | Composiciones y metodos para el tratamiento de melanoma. | |
| MX2023005501A (es) | Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer. | |
| WO2024163641A3 (en) | Formulations for treating cancer | |
| MX2022013867A (es) | Combinacion farmaceutica que comprende tno155 y nazartinib. | |
| MX2023006542A (es) | Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo. |